Monopar Therapeutics vs Mereo BioPharma
MNPR and MREO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MNPR and MREO compare
Monopar Therapeutics is the larger company, worth 2.0 times as much as Mereo BioPharma ($483M against $244M).
Monopar Therapeutics scores higher on the StockData Score (7 against 1 for Mereo BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MNPR | MREO |
|---|---|---|
| Size and price | ||
| Market cap | $483M | $244M |
| Share price | $71.97 | $0.305 |
| Change, 1 year | −17.3% | −82.9% |
| Change, 5 years | 197% | −83.9% |
| Beta (5Y) | 0.66 | 2.15 |
| Employees | 22 | 39 |
| StockData Score | ||
| Total score | 7 (better) | 1 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 3.7× (better) | 10.3× |
| FCF yield | – | −9.1% |
| Profitability | ||
| Return on equity | −19.5% (better) | −76.6% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −440.6× |
| Current ratio | 33.56 (better) | 5.22 |
| Altman Z-score | 69.88 (better) | −2.20 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 92.7% | 7.1% |
| Held by insiders | – | 0.18% |
| Insider net buying, 12 months | −$5.6M | – |
Go deeper
- MNPR stock overview
- MNPR income statement
- MNPR valuation and score
- MREO stock overview
- MREO income statement
- MREO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.